<DOC>
	<DOCNO>NCT02478060</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple administration Birch-SPIRE . To make preliminary assessment pharmacodynamic parameter clinical outcome .</brief_summary>
	<brief_title>Birch-SPIRE Safety Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Male female , age 18 65 year ; Minimum 1 year history rhinitis without conjunctivitis exposure birch pollen Birch IgE â‰¥ 0.35 kU/L Positive skin prick test whole birch allergen Any past history asthma FEV1 &lt; 80 % predict History severe allergic reaction birch allergen , severe drug allergy , severe angioedema severe allergic reaction food Acute phase skin response whole birch allergen mean wheal diameter &gt; 50mm Administration adrenaline ( epinephrine ) contraindicate History severe drug allergy anaphylactic reaction food . History significant disease disorder ( e.g . immune system , pulmonary , cardiovascular , gastrointestinal , liver , renal , neurological , metabolic , malignant , psychiatric , major physical impairment , history alcohol drug abuse )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Birch</keyword>
	<keyword>Rhinitis</keyword>
	<keyword>Rhinoconjuntivitis</keyword>
	<keyword>SPIRE</keyword>
	<keyword>Toleromune</keyword>
</DOC>